The goal of Project 1 is to investigate the role of the cholesteryl ester transfer protein (CETP) in lipoprotein metabolism and atherogenesis and the regulation of CETP gene expression. The experimental approach will place major emphasis on the use of transgenic and knock-out mice. The project is directly related to the major theme of the program project i.e. the investigation of lipid and lipoprotein metabolism and atherogenesis using cell culture models and genetically manipulated mice.
The specific aims are 1) to test the hypothesis that CETP expression increases the atherogenicity of the plasma lipoproteins, by breading the CETP transgene into mice with apoE or LDL receptor genes knocked out; in subsequent studies the effects of hypertriglyceridemia in these models will be examined by making further crosses with other mutant mouse strains; 2) to determine the consequences of CETP expression in adipose tissue and to assess possible in vivo CETP-LPL interactions in m ice with adipose- specific expression of CETP and /or LPL; 3) to define cis- and trans- acting factors mediating sterol regulation and tissue-specific expression of the CETP gene in transgenic mice and in cell culture; and 4) to investigate the function and regulation of alternative splicing of the CETP gene by characterizing transgenic mice expressing an inducible metallothionein-CETP transgene with exon 9 sequences omitted or a natural flanking region CETP transgene with the option to splice out exon 9. These studies will involve extensive interactions without he Transgenesis Core and with Projects 2 (Breslow, LPL), 4 (Jiang, phospholipid transfer protein) and 5 (Smith, apoE). This project will provide new information on the regulation of HDL and VLDL metabolism and on the relationship of HDL to atherogenesis. If CETP has pro-atherogenic activities as suspected, a detailed understanding of the regulation of CETP gene expression may provide a key to decreasing CETP levels as a means of increasing HDL levels and preventing atherosclerosis in humans.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
5P01HL054591-04
Application #
6273083
Study Section
Project Start
1998-07-01
Project End
1999-06-30
Budget Start
1997-10-01
Budget End
1998-09-30
Support Year
4
Fiscal Year
1998
Total Cost
Indirect Cost
Name
Rockefeller University
Department
Type
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Fredman, Gabrielle; Kamaly, Nazila; Spolitu, Stefano et al. (2015) Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7:275ra20
Libby, Peter; Tabas, Ira; Fredman, Gabrielle et al. (2014) Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114:1867-79
Subramanian, Manikandan; Tabas, Ira (2014) Dendritic cells in atherosclerosis. Semin Immunopathol 36:93-102
Subramanian, Manikandan; Hayes, Crystal D; Thome, Joseph J et al. (2014) An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J Clin Invest 124:1296-308
Nagareddy, Prabhakara R; Murphy, Andrew J; Stirzaker, Roslynn A et al. (2013) Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 17:695-708
Subramanian, Manikandan; Thorp, Edward; Hansson, Goran K et al. (2013) Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest 123:179-88
Gautier, Emmanuel L; Westerterp, Marit; Bhagwat, Neha et al. (2013) HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 210:339-53
Rodríguez, José M; Wolfrum, Susanne; Robblee, Megan et al. (2013) Altered expression of Raet1e, a major histocompatibility complex class 1-like molecule, underlies the atherosclerosis modifier locus Ath11 10b. Circ Res 113:1054-64
Tabas, Ira; Glass, Christopher K (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166-72
Rong, James X; Blachford, Courtney; Feig, Jonathan E et al. (2013) ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol 33:4-12

Showing the most recent 10 out of 124 publications